药品注册申请号:017381
申请类型:NDA (新药申请)
申请人:KING PHARMS LLC
申请人全名:KING PHARMACEUTICALS LLC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 SILVADENE SILVER SULFADIAZINE CREAM;TOPICAL 1% Yes Yes AB 1973/11/26 Approved Prior to Jan 1, 1982 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2016/08/01 SUPPL-53(补充) Approval Labeling STANDARD
2015/04/30 SUPPL-52(补充) Approval Manufacturing (CMC) PRIORITY
2013/03/06 SUPPL-50(补充) Approval Labeling STANDARD
2012/11/13 SUPPL-49(补充) Approval Manufacturing (CMC) PRIORITY
2004/01/29 SUPPL-41(补充) Approval Labeling STANDARD
2001/09/27 SUPPL-40(补充) Approval Manufacturing (CMC) PRIORITY
1993/11/04 SUPPL-39(补充) Approval Manufacturing (CMC) PRIORITY
1992/12/07 SUPPL-38(补充) Approval Manufacturing (CMC) PRIORITY
1992/10/05 SUPPL-34(补充) Approval Labeling
1992/02/27 SUPPL-37(补充) Approval Manufacturing (CMC) PRIORITY
1991/05/13 SUPPL-36(补充) Approval Manufacturing (CMC) PRIORITY
1991/01/29 SUPPL-35(补充) Approval Manufacturing (CMC) PRIORITY
1988/11/14 SUPPL-32(补充) Approval Labeling
1987/10/29 SUPPL-31(补充) Approval Manufacturing (CMC) PRIORITY
1986/11/28 SUPPL-30(补充) Approval Labeling
1985/11/15 SUPPL-29(补充) Approval Manufacturing (CMC) PRIORITY
1984/06/12 SUPPL-28(补充) Approval Manufacturing (CMC) PRIORITY
1984/05/31 SUPPL-27(补充) Approval Manufacturing (CMC) PRIORITY
1982/12/06 SUPPL-25(补充) Approval Manufacturing (CMC) PRIORITY
1982/12/06 SUPPL-24(补充) Approval Manufacturing (CMC) PRIORITY
1982/09/15 SUPPL-21(补充) Approval Manufacturing (CMC) PRIORITY
1982/09/10 SUPPL-23(补充) Approval Manufacturing (CMC) PRIORITY
1982/04/19 SUPPL-22(补充) Approval Manufacturing (CMC) PRIORITY
1982/04/19 SUPPL-20(补充) Approval Manufacturing (CMC) PRIORITY
1981/08/28 SUPPL-18(补充) Approval Manufacturing (CMC) PRIORITY
1981/03/04 SUPPL-19(补充) Approval Manufacturing (CMC) PRIORITY
1980/06/26 SUPPL-17(补充) Approval Manufacturing (CMC) PRIORITY
1979/11/26 SUPPL-16(补充) Approval Manufacturing (CMC) PRIORITY
1979/07/06 SUPPL-14(补充) Approval Manufacturing (CMC) PRIORITY
1979/06/14 SUPPL-15(补充) Approval Labeling
1979/04/17 SUPPL-12(补充) Approval Manufacturing (CMC) PRIORITY
1978/09/28 SUPPL-10(补充) Approval Manufacturing (CMC) PRIORITY
1978/07/24 SUPPL-11(补充) Approval Labeling
1978/01/31 SUPPL-9(补充) Approval Manufacturing (CMC) PRIORITY
1977/05/24 SUPPL-6(补充) Approval Manufacturing (CMC) PRIORITY
1977/05/02 SUPPL-7(补充) Approval Manufacturing (CMC) PRIORITY
1977/04/06 SUPPL-8(补充) Approval Manufacturing (CMC) PRIORITY
1977/01/24 SUPPL-4(补充) Approval Manufacturing (CMC) PRIORITY
1975/07/17 SUPPL-2(补充) Approval Manufacturing (CMC) PRIORITY
1974/11/11 SUPPL-1(补充) Approval Labeling
1973/11/26 ORIG-1(原始申请) Approval Type 2 - New Active Ingredient PRIORITY
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:SILVER SULFADIAZINE 剂型/给药途径:CREAM;TOPICAL 规格:1% 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
017381 001 NDA SILVADENE SILVER SULFADIAZINE CREAM;TOPICAL 1% Prescription Yes Yes AB Approved Prior to Jan 1, 1982 KING PHARMS LLC
018578 001 NDA SSD SILVER SULFADIAZINE CREAM;TOPICAL 1% Prescription Yes Yes AB 1982/02/25 DR REDDYS LA
018810 001 NDA THERMAZENE SILVER SULFADIAZINE CREAM;TOPICAL 1% Prescription No No AB 1985/12/23 THEPHARMANETWORK LLC
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database